RT Journal Article
SR Electronic
T1 Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation and Liver Cirrhosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.05.23299538
DO 10.1101/2023.12.05.23299538
A1 Chou, Tien-Shin
A1 Lin, Yuan
A1 Tsai, Ming-Lung
A1 Tseng, Chin-Ju
A1 Dai, Jhih-Wei
A1 Yang, Ning-I
A1 Lin, Chih-Lang
A1 Chen, Li-Wei
A1 Hung, Ming-Jui
A1 Chen, Tien-Hsing
YR 2023
UL http://medrxiv.org/content/early/2023/12/06/2023.12.05.23299538.abstract
AB Background Evidence of the pharmacodynamics of direct oral anticoagulants (DOACs) is limited in patients with atrial fibrillation (AF) and liver cirrhosis (LC). This study aimed to compare the efficacy and safety of DOACs versus warfarin in patients with non-valvular AF and LC.Methods We conducted a new-user, retrospective cohort study involving patients with AF and LC from the Chang Gung Hospital System for the years 2012–2021. LC was categorized per the Child–Pugh classification system. We divided the included patients into two cohorts, namely a DOAC cohort and a warfarin cohort. The measured outcomes were thromboembolic events (ischemic stroke [IS], transient ischemic attack [TIA], and systemic embolism [SE]), intracranial hemorrhage [ICH], gastrointestinal (GI) and major bleeding, and all-cause mortality.Results In total, 478 DOAC users and 247 warfarin users were included in the analysis. DOACs and warfarin exhibited comparable efficacy in preventing thromboembolic events, namely IS (adjusted hazard ratio [aHR], 1.05; 95% confidence interval [CI], 0.42–2.61), TIA (aHR, 1.36; 95% CI, 0.18–10.31]), and SE (aHR, 0.49; 95% CI, 0.14–1.70). DOAC use was associated with a similar risk of ICH (aHR, 0.65; 95% CI, 0.26–1.59) and GI bleeding (aHR, 0.64; 95% CI, 0.39–1.03), a decreased risk of major bleeding (aHR, 0.64; 95% CI, 0.42–0.99), and a reduction in all-cause mortality (aHR, 0.73; 95% CI, 0.54–0.99). Patients with Child– Pugh class A classification exhibited a significant reduction in major bleeding risk in DOAC users (aHR, 0.48; 95% CI, 0.33–0.70); however, this reduction was nonsignificant for patients with class B or C classification (aHR, 0.77; 95% CI, 0.54−1.08)Conclusion Relative to warfarin, DOACs provide comparable efficacy but greater safety for patients with non-valvular AF and LC. Specifically, DOAC use leads to a lower risk of major bleeding and a lower all-cause mortality.What is New?This study reveals that direct oral anticoagulants (DOACs) and warfarin have similar effectiveness in preventing thromboembolic events in patients with non-valvular atrial fibrillation (AF) and liver cirrhosis (LC).DOACs demonstrate a lower risk of major bleeding and reduced all-cause mortality compared to warfarin, especially in patients with Child–Pugh class A LC.The safety profile of DOACs in reducing gastrointestinal bleeding is comparable to that of warfarin, with a trend towards lower risk.What are the Clinical Implications?For patients with non-valvular AF and LC, particularly those with Child–Pugh class A classification, DOACs may be a safer alternative to warfarin due to their lower risk of major bleeding.Clinicians can consider DOACs as a comparable alternative to warfarin for stroke prevention in this patient group, given their similar efficacy in preventing thromboembolic events.The reduced all-cause mortality associated with DOACs highlights their potential benefit in improving overall patient outcomes in the context of AF and LC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Chang Gung Memorial Hospital, Taiwan (CMRPG2N0041).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data were retrieved from the Chang Gung Research Database. Due to retrospective nature of the database study, the hospital identification number of each patient was encrypted and de-identified to protect their privacy. Therefore, informed consent was waived for this study. The institutional review board of Chang Gung Memorial Hospital approved the study protocol (IRB No. :202200625B0).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUpon Request